Answering Key Questions in the Optimal Treatment for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Content Format:

Clinical Thought

Credit Type:

AMA

Credits:

0.25
Répondre aux questions clés concernant le traitement optimal des patients atteints de leucémie lymphoïde chronique récurrente ou réfractaire

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Risposte alle domande chiave sul trattamento ottimale per i pazienti con leucemia linfatica cronica recidivata/refrattaria

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Respondendo a perguntas-chave sobre o tratamento ideal para doentes com leucemia linfocítica crónica recaída/refratária

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Responder a las preguntas clave en el tratamiento óptimo de los pacientes con leucemia linfocítica crónica recidivante/refractaria

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Beantwortung wichtiger Fragen zur optimalen Behandlung von Patientinnen und Patienten mit rezidivierter/refraktärer chronischer lymphatischer Leukämie

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Optimal Therapeutic Sequencing in Relapsed/Refractory CLL for Physicians

Content Format:

Video

Credit Type:

AMA

Credits:

1.25
Optimal Therapeutic Sequencing in Relapsed/Refractory CLL: A Global Perspective

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Optimal Therapeutic Sequencing in Relapsed/Refractory CLL: A Global Perspective

Content Format:

Slideset

Credit Type:

AMA

Credits:

1.00
Perspectiva global sobre los datos de tratamientos emergentes con inhibidores de TQB para LLC y LCM en recidiva/refractarios en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Uma perspectiva global sobre os dados emergentes da terapia com inibidor de BTK para LLC e LCM recidivantes/refratários em 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
Une perspective globale sur les données émergentes relatives à la thérapie par inhibiteurs BTK chez les patients atteints de LLC ou du LCM récidivant/réfractaire en 2022

Content Format:

Text Module

Credit Type:

--

Credits:

--
A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL

Content Format:

Multimedia

Credit Type:

--

Credits:

--
International Experts Address HCP Questions on BTK Inhibitors for CLL and MCL

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL in 2022

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Nouvelles données sur les inhibiteurs de BTK pour la LLC et le LCM : Des experts discutent de l’EHA 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Neue Daten zu BTK-Inhibitoren für CLL und MCL: Expertendiskussion EHA 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Nuovi dati sugli inibitori di BTK nella CLL e MCL: gli esperti discutono lEHA 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Novos dados sobre os inibidores de BTK para LLC e LCM: especialistas discutem o EHA 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Nuevos datos sobre inhibidores de QBT para la LLC y el LCM: expertos hablan sobre la EHA 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
New Data on BTK Inhibitors for CLL and MCL: Experts Discuss EHA 2022

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--